Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.70
TEVA's Cash to Debt is ranked lower than
70% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. TEVA: 0.70 )
Ranked among companies with meaningful Cash to Debt only.
TEVA' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.30 Max: 1.03
Current: 0.7
0.08
1.03
Equity to Asset 0.55
TEVA's Equity to Asset is ranked lower than
60% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TEVA: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
TEVA' s Equity to Asset Range Over the Past 10 Years
Min: 0.4  Med: 0.50 Max: 0.59
Current: 0.55
0.4
0.59
Interest Coverage 10.11
TEVA's Interest Coverage is ranked lower than
66% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.94 vs. TEVA: 10.11 )
Ranked among companies with meaningful Interest Coverage only.
TEVA' s Interest Coverage Range Over the Past 10 Years
Min: 3.6  Med: 12.64 Max: N/A
Current: 10.11
F-Score: 6
Z-Score: 2.22
WACC vs ROIC
5.14%
2.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.88
TEVA's Operating margin (%) is ranked higher than
54% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. TEVA: 9.88 )
Ranked among companies with meaningful Operating margin (%) only.
TEVA' s Operating margin (%) Range Over the Past 10 Years
Min: 8.12  Med: 17.02 Max: 25.46
Current: 9.88
8.12
25.46
Net-margin (%) 8.08
TEVA's Net-margin (%) is ranked higher than
56% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. TEVA: 8.08 )
Ranked among companies with meaningful Net-margin (%) only.
TEVA' s Net-margin (%) Range Over the Past 10 Years
Min: 5.73  Med: 12.03 Max: 20.75
Current: 8.08
5.73
20.75
ROE (%) 6.47
TEVA's ROE (%) is ranked lower than
52% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. TEVA: 6.47 )
Ranked among companies with meaningful ROE (%) only.
TEVA' s ROE (%) Range Over the Past 10 Years
Min: 4.23  Med: 10.00 Max: 16.18
Current: 6.47
4.23
16.18
ROA (%) 3.22
TEVA's ROA (%) is ranked lower than
53% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. TEVA: 3.22 )
Ranked among companies with meaningful ROA (%) only.
TEVA' s ROA (%) Range Over the Past 10 Years
Min: 2.26  Med: 4.98 Max: 9.34
Current: 3.22
2.26
9.34
ROC (Joel Greenblatt) (%) 26.27
TEVA's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. TEVA: 26.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TEVA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 16.82  Med: 33.66 Max: 49.49
Current: 26.27
16.82
49.49
Revenue Growth (3Y)(%) -0.80
TEVA's Revenue Growth (3Y)(%) is ranked lower than
70% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. TEVA: -0.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TEVA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.8  Med: 15.60 Max: 23.4
Current: -0.8
-0.8
23.4
EBITDA Growth (3Y)(%) 6.60
TEVA's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. TEVA: 6.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TEVA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.6  Med: 14.80 Max: 47.4
Current: 6.6
-9.6
47.4
EPS Growth (3Y)(%) -6.80
TEVA's EPS Growth (3Y)(%) is ranked lower than
71% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. TEVA: -6.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TEVA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.5  Med: 15.40 Max: 69.5
Current: -6.8
-25.5
69.5
» TEVA's 10-Y Financials

Financials (Next Earnings Date: 2016-05-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

TEVA Guru Trades in Q2 2015

George Soros 423,308 sh (New)
John Paulson 2,030,500 sh (New)
Larry Robbins 2,844,400 sh (New)
Steven Cohen 179,500 sh (+97.25%)
Jim Simons 2,075,763 sh (+55.03%)
Manning & Napier Advisors, Inc 336,513 sh (+8.06%)
Pioneer Investments 1,155,466 sh (+0.69%)
Ronald Muhlenkamp 176,915 sh (+0.12%)
Bernard Horn 65,600 sh (unchged)
Michael Price 440,300 sh (unchged)
Vanguard Health Care Fund Sold Out
Charles Brandes Sold Out
Andreas Halvorsen Sold Out
Stanley Druckenmiller Sold Out
John Keeley 36,280 sh (-1.51%)
Barrow, Hanley, Mewhinney & Strauss 9,862,843 sh (-3.21%)
David Dreman 90,345 sh (-9.77%)
First Eagle Investment 3,756,998 sh (-10.66%)
Richard Snow 1,603,308 sh (-11.29%)
NWQ Managers 2,984,606 sh (-18.66%)
Paul Tudor Jones 400,000 sh (-27.27%)
Diamond Hill Capital 138,189 sh (-30.78%)
» More
Q3 2015

TEVA Guru Trades in Q3 2015

Andreas Halvorsen 8,872,650 sh (New)
John Paulson 18,000,000 sh (+786.48%)
Steven Cohen 373,800 sh (+108.25%)
Larry Robbins 4,188,779 sh (+47.26%)
Pioneer Investments 1,639,229 sh (+41.87%)
Jim Simons 2,878,763 sh (+38.68%)
First Eagle Investment 4,467,011 sh (+18.90%)
Ronald Muhlenkamp 176,955 sh (+0.02%)
Bernard Horn 65,600 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Michael Price 440,300 sh (unchged)
George Soros Sold Out
Manning & Napier Advisors, Inc 335,793 sh (-0.21%)
John Keeley 35,990 sh (-0.80%)
Barrow, Hanley, Mewhinney & Strauss 9,522,401 sh (-3.45%)
Richard Snow 1,377,992 sh (-14.05%)
NWQ Managers 2,408,826 sh (-19.29%)
David Dreman 42,892 sh (-52.52%)
Diamond Hill Capital 11,525 sh (-91.66%)
Paul Tudor Jones 10,300 sh (-97.43%)
» More
Q4 2015

TEVA Guru Trades in Q4 2015

Louis Moore Bacon 31,994 sh (New)
Vanguard Health Care Fund 5,800,000 sh (New)
Ray Dalio 24,100 sh (New)
John Griffin 4,000,000 sh (New)
Julian Robertson 595,300 sh (New)
Paul Tudor Jones 400,000 sh (+3783.50%)
Andreas Halvorsen 25,043,775 sh (+182.26%)
Larry Robbins 5,955,796 sh (+42.18%)
John Paulson 20,409,300 sh (+13.39%)
John Keeley 36,385 sh (+1.10%)
Barrow, Hanley, Mewhinney & Strauss 9,602,463 sh (+0.84%)
Michael Price 440,300 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Ronald Muhlenkamp 176,955 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Louis Moore Bacon 100,000 sh (unchged)
Samuel Isaly 399,000 sh (unchged)
Diamond Hill Capital Sold Out
David Dreman Sold Out
First Eagle Investment 4,371,619 sh (-2.14%)
Richard Snow 1,262,350 sh (-8.39%)
NWQ Managers 1,380,143 sh (-42.70%)
Manning & Napier Advisors, Inc 113,223 sh (-66.28%)
Pioneer Investments 354,962 sh (-78.35%)
Jim Simons 532,500 sh (-81.50%)
Steven Cohen 28,300 sh (-92.43%)
» More
Q1 2016

TEVA Guru Trades in Q1 2016

Samuel Isaly 399,000 sh (unchged)
Manning & Napier Advisors, Inc 111,192 sh (-1.79%)
» More
» Details

Insider Trades

Latest Guru Trades with TEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF901.002.127 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Guru Investment Theses on Teva Pharmaceutical Industries Ltd

John Keeley Comments on Teva Pharmaceuticals - Apr 26, 2016

Teva Pharmaceuticals (NYSE:TEVA) also had a challenging quarter. Although earnings were in-line with expectations, the company announced that its acquisition of Allergan’s generic pharmaceutical business would be delayed. Subsequent to the failure of the Pfizer/Allergan merger due to the proposed tax inversion regulatory changes, Teva announced that its acquisition of Allergan’s generic business remains on track to close in the second quarter of 2016.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Bernard Horn Comments on Teva Pharmaceutical - Mar 21, 2016

Teva Pharmaceutical (NYSE:TEVA) achieved strong profits, noting better-than-expected Copaxone sales. The company’s strategic initiatives, including the takeover of Allergan’s Actavis generic drug business and the joint venture with Takeda in Japan, were well received. This will further cement Teva’s position as the global leader in generics and help the company negotiate with its customers.

From Bernard Horn (Trades, Portfolio)'s Global Value Fund annual letter 2015.



Check out Bernard Horn latest stock trades

Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd - Mar 27, 2015

We trimmed into strength our position in Teva (TEVA), an Israel-based global biopharmaceutical company specializing in generic formulations. The stock rose substantially on a combination of speculation around M&A in the sector, enthusiasm for the new CEO, and the strong conversion of once-daily Copaxone to the three-times-a-week version.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd - Jun 26, 2014

Generic drug manufacturer Teva Pharmaceutical Industries Ltd. (TEVA) benefitted from the addition of a well-respected CEO and the continued successful transition of patients to a new, patent-protected version of the company’s multiple sclerosis drug.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

John Keeley Comments on Teva Pharmaceuticals Guru stock highlight
Teva Pharmaceuticals (NYSE:TEVA) also had a challenging quarter. Although earnings were in-line with expectations, the company announced that its acquisition of Allergan’s generic pharmaceutical business would be delayed. Subsequent to the failure of the Pfizer/Allergan merger due to the proposed tax inversion regulatory changes, Teva announced that its acquisition of Allergan’s generic business remains on track to close in the second quarter of 2016. Read more...
Health Care Investor Larry Robbins Buys HCA Holdings, Cigna Top 4th quarter buys from Glenview Capital founder
Glenview Capital Management, founded in 2000 by Larry Robbins (Trades, Portfolio), is a privately held investment management firm. During the fourth quarter, he bought shares in many stocks, including the following.  Read more...
Bernard Horn Comments on Teva Pharmaceutical Guru stock highlight
Teva Pharmaceutical (NYSE:TEVA) achieved strong profits, noting better-than-expected Copaxone sales. The company’s strategic initiatives, including the takeover of Allergan’s Actavis generic drug business and the joint venture with Takeda in Japan, were well received. This will further cement Teva’s position as the global leader in generics and help the company negotiate with its customers. Read more...
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Event and distressed strategies investor ups Valeant stake by 50%
John Paulson (Trades, Portfolio) is the president and portfolio manager of Paulson & Co. Inc. Paulson was ranked by Absolute Return Magazine as the third-largest hedge fund in the world managing approximately $29 billion in merger, event and distressed strategies. During the fourth quarter, the guru bought the following stocks. Read more...
Andreas Halvorsen Raises Stake in Teva Pharmaceutical Guru reduces holdings in Netflix, Walgreens Boots Alliance, MasterCard, Alphabet
Andreas Halvorsen (Trades, Portfolio), founding partner and CIO of Viking Global Investors LP, added two dozen stakes to his portfolio in the fourth quarter, but his most noteworthy activity was the increase of his stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), an Israeli pharmaceutical company, by more than 182%. Read more...
Julian Robertson Buys 8 New Stakes in 4th Quarter Guru's investments include Teva Pharmaceutical, Dollar Tree
Julian Robertson (Trades, Portfolio) of Tiger Management made eight new buys in a wide range of sectors in the fourth quarter. His preferred sectors, Technology and Healthcare, were well represented. Read more...
CME Group Among Guru Stocks With Growing Yield Investment ideas with high dividend yields
The following are companies with high and growing dividend yields that gurus are buying according to GuruFocus' All-in-One Screener. Read more...
John Griffin Invests in Teva Pharmaceutical Guru adds to holdings in Autodesk and Allergan in 4th quarter
John Griffin (Trades, Portfolio), president of Blue Ridge Capital, made five new buys in the fourth quarter, three of which had impacts on his portfolio exceeding 1.5%. Read more...
Gurus Are Buying High-Yield Stocks Like WestRock, Target Investment ideas with increasing dividend yields
The following are companies with high and growing dividend yields that gurus are buying according to GuruFocus' All-in-One Screener. Read more...
NWQ Managers Reduces Stakes in Microsoft, MetLife and Teva Pharmaceutical Company cuts 3 stakes by more than 43%
NWQ Managers (Trades, Portfolio) reduced several of its stakes in the third quarter, some by more than 43%. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 29.92
TEVA's P/E(ttm) is ranked lower than
54% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.66 vs. TEVA: 29.92 )
Ranked among companies with meaningful P/E(ttm) only.
TEVA' s P/E(ttm) Range Over the Past 10 Years
Min: 10.53  Med: 20.42 Max: 1072.29
Current: 29.92
10.53
1072.29
Forward P/E 8.92
TEVA's Forward P/E is ranked higher than
78% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.86 vs. TEVA: 8.92 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 29.92
TEVA's PE(NRI) is ranked lower than
54% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.62 vs. TEVA: 29.92 )
Ranked among companies with meaningful PE(NRI) only.
TEVA' s PE(NRI) Range Over the Past 10 Years
Min: 10.53  Med: 20.61 Max: 938.25
Current: 29.92
10.53
938.25
Price/Owner Earnings (ttm) 29.31
TEVA's Price/Owner Earnings (ttm) is ranked higher than
58% of the 259 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.02 vs. TEVA: 29.31 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TEVA' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.82  Med: 20.08 Max: 67.1
Current: 29.31
8.82
67.1
P/B 1.87
TEVA's P/B is ranked higher than
67% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. TEVA: 1.87 )
Ranked among companies with meaningful P/B only.
TEVA' s P/B Range Over the Past 10 Years
Min: 1.36  Med: 2.27 Max: 4.81
Current: 1.87
1.36
4.81
P/S 2.39
TEVA's P/S is ranked higher than
55% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. TEVA: 2.39 )
Ranked among companies with meaningful P/S only.
TEVA' s P/S Range Over the Past 10 Years
Min: 1.58  Med: 3.01 Max: 5.83
Current: 2.39
1.58
5.83
POCF 8.46
TEVA's POCF is ranked higher than
80% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.79 vs. TEVA: 8.46 )
Ranked among companies with meaningful POCF only.
TEVA' s POCF Range Over the Past 10 Years
Min: 6.58  Med: 11.92 Max: 23.43
Current: 8.46
6.58
23.43
EV-to-EBIT 28.80
TEVA's EV-to-EBIT is ranked lower than
67% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.51 vs. TEVA: 28.80 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.4  Med: 20.55 Max: 991
Current: 28.8
11.4
991
EV-to-EBITDA 21.57
TEVA's EV-to-EBITDA is ranked lower than
61% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. TEVA: 21.57 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9  Med: 17.15 Max: 290.6
Current: 21.57
9
290.6
PEG 11.96
TEVA's PEG is ranked lower than
90% of the 279 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.91 vs. TEVA: 11.96 )
Ranked among companies with meaningful PEG only.
TEVA' s PEG Range Over the Past 10 Years
Min: 0.32  Med: 1.10 Max: 119.22
Current: 11.96
0.32
119.22
Shiller P/E 23.78
TEVA's Shiller P/E is ranked higher than
77% of the 145 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.10 vs. TEVA: 23.78 )
Ranked among companies with meaningful Shiller P/E only.
TEVA' s Shiller P/E Range Over the Past 10 Years
Min: 18.72  Med: 31.85 Max: 101.16
Current: 23.78
18.72
101.16
Current Ratio 1.41
TEVA's Current Ratio is ranked lower than
77% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TEVA: 1.41 )
Ranked among companies with meaningful Current Ratio only.
TEVA' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.59 Max: 2.95
Current: 1.41
1.06
2.95
Quick Ratio 1.11
TEVA's Quick Ratio is ranked lower than
71% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. TEVA: 1.11 )
Ranked among companies with meaningful Quick Ratio only.
TEVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.08 Max: 2.18
Current: 1.11
0.69
2.18
Days Inventory 183.28
TEVA's Days Inventory is ranked lower than
78% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. TEVA: 183.28 )
Ranked among companies with meaningful Days Inventory only.
TEVA' s Days Inventory Range Over the Past 10 Years
Min: 131.65  Med: 186.40 Max: 208.14
Current: 183.28
131.65
208.14
Days Sales Outstanding 99.37
TEVA's Days Sales Outstanding is ranked lower than
66% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. TEVA: 99.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 99.37
95.91
153.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.50
TEVA's Dividend Yield is ranked higher than
76% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.56 vs. TEVA: 2.50 )
Ranked among companies with meaningful Dividend Yield only.
TEVA' s Dividend Yield Range Over the Past 10 Years
Min: 0.49  Med: 1.22 Max: 3.26
Current: 2.5
0.49
3.26
Dividend Payout 0.75
TEVA's Dividend Payout is ranked lower than
85% of the 371 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. TEVA: 0.75 )
Ranked among companies with meaningful Dividend Payout only.
TEVA' s Dividend Payout Range Over the Past 10 Years
Min: 0.05  Med: 0.16 Max: 0.86
Current: 0.75
0.05
0.86
Dividend Growth (3y) 9.80
TEVA's Dividend Growth (3y) is ranked higher than
55% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. TEVA: 9.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
TEVA' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -6.7  Med: 27.00 Max: 80.9
Current: 9.8
-6.7
80.9
Forward Dividend Yield 2.50
TEVA's Forward Dividend Yield is ranked higher than
71% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. TEVA: 2.50 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.12
TEVA's Yield on cost (5-Year) is ranked higher than
85% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. TEVA: 5.12 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TEVA' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.01  Med: 2.51 Max: 6.7
Current: 5.12
1.01
6.7
3-Year Average Share Buyback Ratio 0.30
TEVA's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 466 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -3.30 vs. TEVA: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.9  Med: -3.60 Max: 2.6
Current: 0.3
-10.9
2.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.08
TEVA's Price/Projected FCF is ranked higher than
83% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. TEVA: 1.08 )
Ranked among companies with meaningful Price/Projected FCF only.
TEVA' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.66  Med: 1.51 Max: 7.38
Current: 1.08
0.66
7.38
Price/DCF (Earnings Based) 2.31
TEVA's Price/DCF (Earnings Based) is ranked lower than
77% of the 71 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. TEVA: 2.31 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.80
TEVA's Price/Median PS Value is ranked higher than
80% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. TEVA: 0.80 )
Ranked among companies with meaningful Price/Median PS Value only.
TEVA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.53  Med: 1.03 Max: 1.85
Current: 0.8
0.53
1.85
Earnings Yield (Greenblatt) (%) 3.50
TEVA's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. TEVA: 3.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TEVA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 4.90 Max: 8.8
Current: 3.5
0.1
8.8
Forward Rate of Return (Yacktman) (%) -9.29
TEVA's Forward Rate of Return (Yacktman) (%) is ranked lower than
78% of the 316 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. TEVA: -9.29 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TEVA' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -10  Med: 22.05 Max: 43.7
Current: -9.29
-10
43.7

More Statistics

Revenue(Mil) $19652
EPS $ 1.82
Beta0.58
Short Percentage of Float2.47%
52-Week Range $52.62 - 72.31
Shares Outstanding(Mil)907.66

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 23,732 25,160 26,046
EPS($) 5.60 6.10 6.59
EPS without NRI($) 5.60 6.10 6.59

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, TSE:4502, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVJF.USA,
Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments such as generic products, which includes chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as API business; and specialty products, which includes several core franchises, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women's health. In addition to these two segments, the Company has other activities, primarily PGT Healthcare, OTC joint venture with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices. The Company, along with its subsidiaries operates in approximately 60 countries. It develops, manufactures and sell generic pharmaceutical products in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. Specialty medicines business, which is focused on delivering solutions to patients and providers via medicines, devices and services in all key regions and markets around the world, includes several core therapeutic areas, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines. Some of its products are Copaxone, Azilect & Provigil, among others. The Company markets approximately 375 generic products in more than 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").
» More Articles for TEVA

Headlines

Articles On GuruFocus.com
John Keeley Comments on Teva Pharmaceuticals Apr 26 2016 
Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 
Time To Buy Allergan Apr 06 2016 
Health Care Investor Larry Robbins Buys HCA Holdings, Cigna Mar 31 2016 
Fight Market Malaise with These Four Sector Strategies Mar 30 2016 
Bernard Horn Comments on Teva Pharmaceutical Mar 21 2016 
Polaris Global Value Fund Annual Letter 2015 Mar 21 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
Andreas Halvorsen Raises Stake in Teva Pharmaceutical Mar 09 2016 
Julian Robertson Buys 8 New Stakes in 4th Quarter Mar 09 2016 

More From Other Websites
8:01 am Teva Pharma announces FDA approval of Proair Respiclick inhalation powder for pediatric... Apr 29 2016
Teva Announces FDA Approval of ProAir RespiClick® (albuterol sulfate) Inhalation Powder for... Apr 29 2016
Major Pharma Short Interest Remains Mixed, With 1 Massive Drop Apr 27 2016
Teva migraine awareness campaign features Hollywood actress Apr 26 2016
Jennifer Morrison Reveals How Her Journey with Migraine is More Than a Headache Apr 25 2016
Goldman Sach's 5 Large-Cap Pharma Stock Favorites Ahead of Earnings Apr 25 2016
A Look at Zach Schreiber’s Top Picks Ahead of His Ira Sohn Presentation Apr 21 2016
Teva to Report First Quarter 2016 Financial Results on May 9, 2016 Apr 18 2016
Teva Presents New Data for SD-809 in Huntington Disease at 68th American Academy of Neurology (AAN)... Apr 18 2016
Allergan's Outlook Brightens as Generics Sale Seems on Track Apr 15 2016
Why Has Teva Pharmaceutical Targeted Orphan Diseases? Apr 14 2016
CIO Voices: Allergan's Sean Lennon Says Never Presume Job Security in a Merger Apr 13 2016
Teva Pharmaceutical: Label Expansion Plans in 2016 Apr 13 2016
You Can’t Smooth The Bumps Apr 12 2016
Short Sellers Become More Selective in Major Pharma Apr 12 2016
Teva to Present Data Highlighting Company’s Pipeline in Neurological Disorders at 68th AAN Annual... Apr 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK